Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets
- PMID: 19193792
- PMCID: PMC2663257
- DOI: 10.1128/JVI.02453-08
Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets
Abstract
The type I interferon (IFN) response represents one of the first lines of defense against influenza virus infections. In this study, we assessed the protective potential of exogenous IFN-alpha against seasonal and highly pathogenic influenza viruses in ferrets. Intranasal treatment with IFN-alpha several hours before infection with the H1N1 influenza A virus strain A/USSR/90/77 reduced viral titers in nasal washes at least 100-fold compared to mock-treated controls. IFN-treated animals developed only mild and transient respiratory symptoms, and the characteristic fever peak seen in mock-treated ferrets 2 days after infection was not observed. Repeated application of IFN-alpha substantially increased the protective effect of the cytokine treatment. IFN-alpha did not increase survival after infection with the highly pathogenic H5N1 avian influenza A virus strain A/Vietnam/1203/2004. However, viral titers in nasal washes were significantly reduced at days 1 and 3 postinfection. Our study shows that intranasal application of IFN-alpha can protect ferrets from seasonal influenza viruses, which replicate mainly in the upper respiratory tract, but not from highly pathogenic influenza viruses, which also disseminate to the lung. Based on these results, a more intensive evaluation of IFN-alpha as an emergency drug against pandemic influenza A is warranted.
Figures
![FIG. 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2663257/bin/zjv0080917420001.gif)
![FIG. 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2663257/bin/zjv0080917420002.gif)
![FIG. 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2663257/bin/zjv0080917420003.gif)
![FIG. 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2663257/bin/zjv0080917420004.gif)
![FIG. 5.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2663257/bin/zjv0080917420005.gif)
Similar articles
-
M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.Vaccine. 2017 Jul 24;35(33):4177-4183. doi: 10.1016/j.vaccine.2017.06.039. Epub 2017 Jun 28. Vaccine. 2017. PMID: 28668565 Free PMC article.
-
Characterization of the Localized Immune Response in the Respiratory Tract of Ferrets following Infection with Influenza A and B Viruses.J Virol. 2015 Dec 30;90(6):2838-48. doi: 10.1128/JVI.02797-15. J Virol. 2015. PMID: 26719259 Free PMC article.
-
Sequential seasonal H1N1 influenza virus infections protect ferrets against novel 2009 H1N1 influenza virus.J Virol. 2013 Feb;87(3):1400-10. doi: 10.1128/JVI.02257-12. Epub 2012 Oct 31. J Virol. 2013. PMID: 23115287 Free PMC article.
-
Low-dose interferon Type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitro and in vivo.J Interferon Cytokine Res. 2011 Jun;31(6):515-25. doi: 10.1089/jir.2010.0071. Epub 2011 Feb 16. J Interferon Cytokine Res. 2011. PMID: 21323570
-
Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding.J Virol. 2009 Apr;83(7):2851-61. doi: 10.1128/JVI.02174-08. Epub 2009 Jan 14. J Virol. 2009. PMID: 19144714 Free PMC article.
Cited by
-
Induction of Interferon-Stimulated Genes Correlates with Reduced Growth of Influenza A Virus in Lungs after RIG-I Agonist Treatment of Ferrets.J Virol. 2022 Aug 24;96(16):e0055922. doi: 10.1128/jvi.00559-22. Epub 2022 Aug 2. J Virol. 2022. PMID: 35916513 Free PMC article.
-
Early IFN-β administration protects cigarette smoke exposed mice against lethal influenza virus infection without increasing lung inflammation.Sci Rep. 2022 Mar 8;12(1):4080. doi: 10.1038/s41598-022-08066-7. Sci Rep. 2022. PMID: 35260752 Free PMC article.
-
Isorhamnetin inhibits amplification of influenza A H1N1 virus inflammation mediated by interferon via the RIG-I/JNK pathway.Ann Transl Med. 2021 Aug;9(16):1327. doi: 10.21037/atm-21-3532. Ann Transl Med. 2021. PMID: 34532464 Free PMC article.
-
Dynamically linking influenza virus infection kinetics, lung injury, inflammation, and disease severity.Elife. 2021 Jul 20;10:e68864. doi: 10.7554/eLife.68864. Elife. 2021. PMID: 34282728 Free PMC article.
-
Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections.Front Immunol. 2021 May 19;12:660298. doi: 10.3389/fimmu.2021.660298. eCollection 2021. Front Immunol. 2021. PMID: 34093548 Free PMC article. Review.
References
-
- Beilharz, M. W., J. M. Cummins, and A. L. Bennett. 2007. Protection from lethal influenza virus challenge by oral type 1 interferon. Biochem. Biophys. Res. Commun. 355740-744. - PubMed
-
- Boltz, D. A., J. E. Rehg, J. McClaren, R. G. Webster, and E. A. Govorkova. 2008. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. J. Infect. Dis. 1971315-1323. - PubMed
-
- Borecky, L., and N. Fuchsberger. 1983. Interferon as therapeutic agent. Acta Virol. 27359-370. - PubMed
-
- Enserink, M. 2004. Influenza. W. H. O. adds more “1918” to pandemic predictions. Science 3062025. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical